Evidence map›Paper›PMID 36979817›Full record

ArticleBiomedicines2023

Mid-Infrared Spectroscopy as a New Tool for Ruling Out Spontaneous Bacterial Peritonitis: A Proof-of-Concept Study.

Marwin A Farrugia, Maëna Le Corvec, Christophe Renou, Jean-Baptiste Nousbaum, Dann J Ouizeman, Olivier Sire, Olivier Loréal, Hugues Tariel, Jérôme Bernard, Thierry Piche and 6 more

Open access · goldFull text read
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Marwin A FarrugiaService d'Hépatologie, Centre Hospitalier Universitaire, Hôpital Archet 2, 151 Route de Saint-Antoine, 06000 Nice, France.ORCID 0000-0001-5264-5925
Maëna Le CorvecDIAFIR, Avenue Chardonnet, Parc Lorans 26J, 35000 Rennes, France.
Christophe RenouCentre Hospitalier de Hyères, Bd Maréchal Juin, 83400 Hyères, France.
Jean-Baptiste NousbaumCentre Hospitalier Régional Universitaire de Brest, 2, Avenue Foch, 29609 Brest, France.
Dann J OuizemanService d'Hépatologie, Centre Hospitalier Universitaire, Hôpital Archet 2, 151 Route de Saint-Antoine, 06000 Nice, France.
Olivier SireIRDL, UMR CNRS 6027, Université Bretagne Sud, 56000 Vannes, France.ORCID 0000-0003-1126-8646
Olivier LoréalNUMECAN, UMR INSERM 1241, Centre Hospitalier Universitaire, 35000 Rennes, France.
Hugues TarielDIAFIR, Avenue Chardonnet, Parc Lorans 26J, 35000 Rennes, France.
Jérôme BernardDIAFIR, Avenue Chardonnet, Parc Lorans 26J, 35000 Rennes, France.
Thierry PicheINSERM, U1065, C3M, Université Côte d'Azur, 06000 Nice, France.
Albert TranService d'Hépatologie, Centre Hospitalier Universitaire, Hôpital Archet 2, 151 Route de Saint-Antoine, 06000 Nice, France.
Hafid Ait-OufellaService de Réanimation Médicale, AP-HP, Hôpital Saint-Antoine, INSERM UMR 991, Inserm U970, Paris Research Cardiovascular Center, Université Pierre et Marie Curie, 75012 Paris, France.
Luce LandraudUniversité Paris Cité and Université Sorbonne Paris Nord, INSERM, IAME, Louis Mourier Hospital, 92700 Paris, France.
Philippe GualINSERM, U1065, C3M, Université Côte d'Azur, 06000 Nice, France.
Rodolphe AntyService d'Hépatologie, Centre Hospitalier Universitaire, Hôpital Archet 2, 151 Route de Saint-Antoine, 06000 Nice, France.ORCID 0000-0001-8194-9805
The Cytokine Ascites Group
Inserm · FRDiafir (France) · FRHôpital l'Archet · FRCentre Hospitalier Régional Universitaire de Brest · FRCentre National de la Recherche Scientifique · FR

Funding

"Investments for the Future" LABEX SIGNALIFE; UCAJEDI Investments in the Future project #ANR-11-LABX-0028-01; #ANR-15-IDEX-01National Research Agency #ANR-18-CE14-0019-02, #ANR-19-CE14-0044-01
6 · The paper itself

Abstract

BACKGROUND AND

aimsA highly sensitive and specific point-of-care method for diagnosing spontaneous bacterial peritonitis (SBP) is currently lacking. The objective of the present study is to evaluate the diagnostic value of a rapid, easy-to-use, mid-infrared fiber evanescent wave spectroscopy (MIR-FEWS) method for ruling out SBP. PATIENTS AND

methodsCirrhotic patients (

resultsMost of the patients were male (71%). The mean age was 60.25 years. Alcohol-related liver disease was the most common cause of cirrhosis. SBP was observed in 18% of the patients. For the diagnosis of SBP in the calibration and validation groups, respectively, the model gave areas under the receiver operating characteristic curves of 0.87 and 0.89, sensitivities of 90% and 87%, specificities of 78% and 80%, positive predictive values of 48% and 50%, negative predictive values of 97% and 96%, positive likelihood ratio of 4.09 and 4.35, negative likelihood ratio of 0.13 and 0.16, Youden index of 0.68 and 0.67, and correct classification rates of 80% and 81%.

conclusionThe results of this proof-of-concept study show that MIR-FEWS is a highly sensitive diagnostic method for ruling out SBP. The method warrants further investigation.

Indexed as

ascites fluidcirrhosisinfectionmid-infrared spectroscopyspontaneous bacterial peritonitis

Identifiers

PMID36979817
PMCPMC10045833
OpenAlexW4323841543

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read25
identifiers read1
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.